Using of gonadotropin releasing hormone antagonist in in vitro fertilization and embryo transfer

AIM: To evaluate the efficacy of gonadotropin releasing hormone antagonist (GnRHanta) in in vitro fertilization and embryo transfer. METHODS: Data of 384 cycles of in vitro fertilization and embryo transfer performed in our Reproductive Medicine Center from March 2003 to August 2004, were analyzed retrospectively. Patients were divided into two groups: study group, 60 cycles using GnRHanta for controlled ovarian hyperstimulation; control group, 324 cycles using GnRH analogue (GnRHa) for controlled ovarian hyperstimulation. RESULTS: The dose of gonadotrophin used in study group, (2 625±s 895) IU, was much less than that in control group ((3075±775) IU, P 0.01) . The cleavage rate and the number of gradeⅢembryo in study group increased more than those in control group (P 0.05, P 0.01) . There were no statistical differences in the durations of treatment, the amounts of oocyte retrieved, the rates of luteal hormone (LH) surge occurring, the rates of ovulating before oocyte retrieved, the fertilization rates, the number of gradeⅠ/Ⅱ/Ⅳembryos, outcomes of pregnancy, and the rates of ovarian hyperstimulation syndrome between the two groups (P 0.05) . CONCLUSION: GnRHanta protocol is a simple, economic, and effective protocol, and deserves to be popularized in in vitro fertilization and embryo transfer.